Italian Medicines Agency(AIFA)

What Italian Medicines Agency(AIFA) does

AIFA (Agenzia Italiana del Farmaco) is Italy's national regulatory authority for medicinal products, operating under the supervision of the Italian Ministry of Health. Established by Article 48 of Law 269/2003 and operational since 2004, the agency is headquartered in Rome and holds exclusive jurisdiction over drug marketing authorization, pricing and reimbursement negotiation with the National Health Service (SSN), pharmacovigilance oversight via the National Pharmacovigilance Network (Rete Nazionale di Farmacovigilanza), and clinical trial authorization through the Osservatorio Nazionale Sperimentazione Clinica (OsSC). AIFA also operates the Scientific and Economic Committee (CSE) for reimbursement decisions and funds independent research, including €17,554,208 allocated across 19 rare disease projects.

AIFA's technology stack includes the Banca Dati dei Farmaci national drug database, the OsMed Interattivo platform for pharmaceutical consumption and expenditure analytics, the Registri di Monitoraggio for tracking reimbursed medicines, the Open Data Portal (CC-BY 4.0), and two mobile applications (AIFA Medicinali and Firstline AIFA Antibiotici). The agency is undergoing a digital transformation programme funded by Italy's National Recovery and Resilience Plan (PNRR), encompassing migration to the National Strategic Cloud (Polo Strategico Nazionale, completed February 2025), a €480,000 cybersecurity programme aligned with NIS 2 requirements, and a data interoperability project on the National Data Platform (PDND) with 6 planned API interfaces.

AIFA is funded through Italian state budget allocations and regulatory fees charged to pharmaceutical companies, including annual fees for marketing authorizations (AIC) and tariffs for medical-scientific conference and congress authorizations under Article 124 of Legislative Decree 219/2006 (per Ministerial Decree of 6 December 2016, adjusted annually by ISTAT). The agency operates on a non-profit public service basis and does not generate commercial revenue. Its customer base comprises the full universe of pharmaceutical companies with marketing authorizations in Italy, Italian healthcare professionals, and Italian citizens, served through self-service online portals, mobile applications, the FarmaciLine telephone hotline (800.571.661), and social media channels.

Name

Italian Medicines Agency(AIFA)

Legal name

Agenzia Italiana del Farmaco

Website

https://aifa.gov.it

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

101–250 employees

Short description

AIFA is Italy's national medicines regulatory authority under the Ministry of Health, responsible for drug marketing authorization, pricing and reimbursement negotiation, pharmacovigilance oversight, and clinical trial authorization, serving pharmaceutical companies, healthcare professionals, and citizens through centralized regulatory and digital information services.

Ownership category

akta.pro rank

Product category

Pharmaceutical Regulatory Services

akta.pro primary industry

Medical Device Regulators (HLAJADAC)

akta.pro secondary industries

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ), Regulatory Readiness & Audit Automation (e.g., EU AI Act, NIST AI RMF, ISO/IEC 42001) (HDAAAMAE)

Keywords

• Pharmaceutical regulation
• Drug authorization services
• Pharmacovigilance oversight
• Medicines pricing reimbursement
• Clinical trial regulation

Headquarters

HQ city

Rome

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Government Funding and Regulatory Fees: AIFA operates as a government regulatory agency funded through state budget allocations and regulatory fees charged to pharmaceutical companies. Revenue is derived from: (1) annual fees from pharmaceutical companies for marketing authorizations (AIC), (2) fees for conference and congress authorizations under Article 124 of Legislative Decree 219/2006, (3) tariff payments for various regulatory services, and (4) government budget allocations. The agency does not generate commercial revenue but operates on a non-profit public service basis.

Pricing tiers

Distribution channels5 records

Marketing channels6 records

Core offering

AIFA is the national regulatory authority of Italy responsible for authorizing medicinal products for the Italian market, negotiating pricing and reimbursement with the National Health Service, overseeing pharmacovigilance and drug safety monitoring, authorizing and tracking clinical trials, and managing monitoring registers for reimbursed medicines. The agency also operates digital information services — including mobile applications, drug databases, and open-data portals — that provide drug information to healthcare professionals, pharmaceutical companies, and citizens.

Product overview

The Italian Medicines Agency (AIFA) provides a comprehensive suite of digital services for pharmaceutical regulation in Italy. The agency's offerings include the AIFA Medicinali mobile app and Firstline AIFA antibiotic app for citizens and healthcare professionals; the Banca Dati dei Farmaci drug database; OsMed Interattivo for pharmaceutical consumption analytics; Registri di Monitoraggio for tracking reimbursed medicines; and an Open Data Portal providing access to clinical trials, pharmacovigilance, and expenditure data. Administrative services include the Autorizzazione Convegni e Congressi online platform for pharmaceutical company event authorization and TrovaNormeFarmaco for accessing official resolutions.

Differentiator

Problem solved

Functional benefit

Brands

• FarmaciLine: Telephone information service for questions regarding efficacy, safety, and availability of medicines, reachable at 800.571.661
• OsMed (Osservatorio Impiego Medicinali)
• AIFA Medicinali App
• Firstline AIFA - Antibiotici

Products and services

• AIFA Medicinali App

Quantifiable outcome

• 17,554,208 euros allocated to 19 independent rare disease research projects
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability1 record

Feature6 records

Partnerships

One partnership is on record.

• Federazione Ordini Farmacisti Italiani (FOFI)flagshipStrategic or Co-development Partner · 17 June 2026AIFA and FOFI signed a collaboration agreement for digital innovation in the pharmaceutical sector. The partnership focuses on developing interoperable tools based on artificial intelligence to support pharmacists. This strategic collaboration aims to enhance pharmaceutical services through technology integration.

Scale indicators5 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Health Canada — Health Products and Food Branch: Canada's national authority for drug and health product regulation, performing equivalent drug authorization, safety monitoring, and clinical trial oversight functions. Comparable institutional scale and regulatory mandate within a single national jurisdiction.
• Swissmedic: Switzerland's national medicines and medical devices authority, performing equivalent drug authorization and pharmacovigilance functions. Comparable size and scope, and a frequent collaboration partner for AIFA within bilateral European regulatory networks.
• Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM): Germany's federal institute for drugs and medical devices, the closest direct counterpart to AIFA in scope and function. Handles drug authorization, pharmacovigilance, and clinical trial oversight within its national jurisdiction with a similar federal agency structure.
• Therapeutic Goods Administration (TGA): Australia's regulator for therapeutic goods including prescription medicines, vaccines, and medical devices. Performs drug authorization, pharmacovigilance, and listing functions comparable to AIFA, serving as a like-sized national regulatory counterpart.
• Agence nationale de sécurité du médicament (ANSM): France's national medicines agency with equivalent responsibilities for drug authorization, safety surveillance, and market oversight. Operates with similar institutional model under national health authority supervision, making it one of the most direct functional peers for AIFA.
• Pharmaceuticals and Medical Devices Agency (PMDA): Japan's national agency for drug and medical device review, safety, and post-marketing surveillance. Operates a comparable model of centralized authorization with strong government backing and integration with international regulatory frameworks.
• Medicines and Healthcare products Regulatory Agency (MHRA): UK's medicines and medical devices regulator. Despite post-Brexit divergence, MHRA remains a direct functional peer for drug approval, pharmacovigilance, and clinical trial authorization, with a comparable mix of national and EU-aligned regulatory obligations.

Broad incumbents

• National Medical Products Administration (NMPA): China's national regulator for drugs, medical devices, cosmetics, and food. Significantly larger scale than AIFA but operates an analogous central authorization and pharmacovigilance model increasingly relevant as Italian pharmaceutical companies engage with Chinese markets.
• U.S. Food and Drug Administration (FDA): The global benchmark for drug and medical device regulation, with much broader scope (food, cosmetics, devices, tobacco, drugs). AIFA's regulatory decisions and pricing practices often benchmarked against FDA precedents, making it a comparable incumbent despite jurisdictional differences.
• European Medicines Agency (EMA): EU-level medicines regulator coordinating approval, pharmacovigilance, and clinical trial oversight across member states including Italy. Directly comparable in regulatory function but operates at multi-country scope, overlapping with AIFA's mandate rather than competing with it directly.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/aifa_ufficiale
• YouTubeyoutube.com/channel/UCMDgZt1zx9-Kwr0811jY4PQ
• Facebookfacebook.com/AIFAufficiale
• LinkedInlinkedin.com/company/aifa-agenzia-italiana-del-farmaco
• Instagraminstagram.com/aifa_agenziafarmaco

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Italian Medicines Agency(AIFA)